29 March 2011
Trials for a new lung cancer treatment have begun in Oxford.
The experimental treatment is aimed at patients who have failed to respond to traditional chemotherapy medication.
Dr Denis Talbot, trial chief investigator at the new Oxford Cancer Research Centre, said: "We hope that it may increase rates of survival for lung cancer patients."
He claimed that preliminary results were encouraging and that if the benefits were borne out in this more substantial trial then the drug could be developed into a clinical treatment.
Dr Talbot said that late diagnosis was one of the issues of lung cancer treatment.
"The majority, 65-75 per cent, of lung cancer patients are diagnosed when the cancer has already become aggressive, which makes it more difficult to treat successfully," he said.
"There's an urgent need to develop new medicines which may provide additional options for these patients," he concluded.
Posted by Philip Briggs
Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.